FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

on, D.C. 20549	
on, D.C. 20049	OMB APPROVAL

- 1	OWID ALT NOVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

	Check this box if no longer subject to
ì	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Welley Manley D.  1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol TherapeuticsMD, Inc. [TXMD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Walker Marlan D</u>					Therapeuticonis, inc. [ TAMD ]								Direc	tor	10% Owner		ner	
													X Office below	er (give title v)		Other (s <sub>l</sub> below)	pecify	
(Last)	`	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)								General Counsel					
951 YAMATO ROAD					03/14/2022													
SUITE 220																		
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
BOCA R	ATON F	L	33431										X Form	filed by Or	ne Repor	ting Person		
													Form	filed by Mo	ore than	One Reporti	ng Person	
(City)	(\$	State)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date					saction //Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			es Acquire Of (D) (Inst	i (A) or : 3, 4 and	Benefi Owned	ties cially Following	Form	Direct III Indirect Estr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			1	Instr. 4)	
Common Stock 03/14				03/14/	4/2022		М		230,000 A		(1)	2	258,908		D			
							ities Acqui warrants,						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code (Instr				6. Date Exercisable and Expiration Date (Month/Day/Year)			of Securi Underlyir	ig e Security	8. Price Derivat Securit (Instr. 5	ve deriva Securi	ties cially I ing	f 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Share	s	Transa (Instr.	ction(s)			
Restricted Stock Units	\$0.00	03/14/2022		М		230,000(1)(2)		(3)		(3)	Common Stock	230,00	0 \$0.00		0	D		

## Explanation of Responses:

- 1. On March 14, 2022, the reporting person received 230,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on December 13, 2021.
- 2. Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
- 3. The RSUs vested on December 13, 2021.

## Remarks:

/s/ Marlan D. Walker

03/15/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.